诺瓦瓦克斯医药宣布,其与Sanofi共同开发的组合产品(包括该公司的新冠疫苗)符合条件,未来有望获得高达3.5亿美元的里程碑付款。
诺瓦瓦克斯医药宣布,其与Sanofi共同开发的组合产品(包括该公司的新冠疫苗)符合条件,未来有望获得高达3.5亿美元的里程碑付款。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.